Cargando…
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction
AIMS: This study aims to improve risk stratification for primary prevention implantable cardioverter defibrillator (ICD) implantation by developing a new mutation-specific prediction model for malignant ventricular arrhythmia (VA) in phospholamban (PLN) p.Arg14del mutation carriers. The proposed mod...
Autores principales: | Verstraelen, Tom E, van Lint, Freyja H M, Bosman, Laurens P, de Brouwer, Remco, Proost, Virginnio M, Abeln, Bob G S, Taha, Karim, Zwinderman, Aeilko H, Dickhoff, Cathelijne, Oomen, Toon, Schoonderwoerd, Bas A, Kimman, Gerardus P, Houweling, Arjan C, Gimeno-Blanes, Juan R, Asselbergs, Folkert W, van der Zwaag, Paul A, de Boer, Rudolf A, van den Berg, Maarten P, van Tintelen, J Peter, Wilde, Arthur A M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325776/ https://www.ncbi.nlm.nih.gov/pubmed/34113975 http://dx.doi.org/10.1093/eurheartj/ehab294 |
Ejemplares similares
-
The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
por: Van Der Heide, M Y C, et al.
Publicado: (2023) -
A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
por: de Brouwer, Remco, et al.
Publicado: (2023) -
Recurrent and founder mutations in the Netherlands—Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy
por: van der Zwaag, P. A., et al.
Publicado: (2013) -
Prevalence and cardiac phenotype of patients with a phospholamban mutation
por: Hof, I. E., et al.
Publicado: (2018) -
Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
por: te Rijdt, W. P., et al.
Publicado: (2021)